{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:10:31Z","timestamp":1793801431302,"version":"4.6.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Reactivation of latent cytomegalovirus (CMV) is increased in recipients of allogeneic hematopoietic cell transplantation (allo-HCT) with seropositive CMV using posttransplant cyclophosphamide (PT-Cy)\u2013based graft-versus-host disease (GVHD) prophylaxis. Letermovir, a novel DNA terminase complex inhibitor, reduces the incidence of clinically significant CMV infection (csCMVi) in this population; however, parameters that predict csCMVi after letermovir withdrawal are not well described. Here, we examined clinical and immunological parameters in 294 recipients of PT-Cy\u2013based allo-HCT, including 157 patients with CMV, of whom 80 completed letermovir prophylaxis without csCMVi and subsequently stopped letermovir. In this population, the median duration of letermovir exposure was 203\u00a0days (interquartile range [IQR], 160-250\u00a0days). After letermovir withdrawal, the 90-day cumulative incidence of csCMVi was 23.0% (95% confidence interval, 14.3-32.8). There were no episodes of CMV end-organ disease. Hypogammaglobulinemia before letermovir discontinuation was predictive of csCMVi (hazard ratio, 0.33; 95% confidence interval, 0.12-0.93; P\u00a0= .03), whereas T-cell and B-cell reconstitution before letermovir withdrawal were not predictive of csCMVi. Higher numbers of natural killer cells were found before letermovir withdrawal in patients who experienced csCMVi (median, 202 vs 160; P\u00a0= .03). In recipients with seropositive CMV, CD3+CD4\u2013CD8+ T-cell reconstitution was faster in patients with CMV regardless of letermovir exposure. Taken together, these data suggest that csCMVi after letermovir withdrawal was frequent in patients treated with PT-Cy, despite prolonged exposure. Strategies to boost CMV-specific adaptive immunity in patients with persistent hypogammaglobulinemia is a logical pathway to reduce csCMVi after letermovir withdrawal.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010966","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T17:02:35Z","timestamp":1698771755000},"page":"7153-7160","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide\u2013based transplant"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-142X","authenticated-orcid":false,"given":"Andrew","family":"Lin","sequence":"first","affiliation":[{"name":"1Adult BMT Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-974X","authenticated-orcid":false,"given":"Samantha","family":"Brown","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-9346","authenticated-orcid":false,"given":"Stephanie","family":"Chinapen","sequence":"additional","affiliation":[{"name":"1Adult BMT Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Joo","family":"Lee","sequence":"additional","affiliation":[{"name":"3Infectious Diseases Service, Division of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Department of Internal Medicine, Weill Cornell Medical School, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Seo","sequence":"additional","affiliation":[{"name":"3Infectious Diseases Service, Division of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Department of Internal Medicine, Weill Cornell Medical School, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9422-5766","authenticated-orcid":false,"given":"Doris M.","family":"Ponce","sequence":"additional","affiliation":[{"name":"1Adult BMT Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Department of Internal Medicine, Weill Cornell Medical School, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Shahid","sequence":"additional","affiliation":[{"name":"3Infectious Diseases Service, Division of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Department of Internal Medicine, Weill Cornell Medical School, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"1Adult BMT Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Department of Internal Medicine, Weill Cornell Medical School, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa A.","family":"Papanicolaou","sequence":"additional","affiliation":[{"name":"3Infectious Diseases Service, Division of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Department of Internal Medicine, Weill Cornell Medical School, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"1Adult BMT Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Department of Internal Medicine, Weill Cornell Medical School, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3433-9179","authenticated-orcid":false,"given":"Brian C.","family":"Shaffer","sequence":"additional","affiliation":[{"name":"1Adult BMT Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Department of Internal Medicine, Weill Cornell Medical School, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"issue":"7","key":"2023121116132415500_bib1","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-019-03669-z","article-title":"The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT","volume":"98","author":"Schmidt-Hieber","year":"2019","journal-title":"Ann Hematol"},{"issue":"19","key":"2023121116132415500_bib2","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"issue":"20","key":"2023121116132415500_bib3","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2023121116132415500_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"2023121116132415500_bib5","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"2023121116132415500_bib6","first-page":"269","article-title":"Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus","volume":"8","author":"Melendez","year":"2015","journal-title":"Infect Drug Resist"},{"issue":"16","key":"2023121116132415500_bib7","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/bloodadvances.2021004362","article-title":"Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients","volume":"5","author":"Hill","year":"2021","journal-title":"Blood Adv"},{"key":"2023121116132415500_bib8","doi-asserted-by":"crossref","first-page":"740079","DOI":"10.3389\/fonc.2021.740079","article-title":"Letermovir prophylaxis for cytomegalovirus infection in allogeneic stem cell transplantation: a real-world experience","volume":"11","author":"Martino","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"2023121116132415500_bib9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciab1064","article-title":"Impact of letermovir primary cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: a retrospective cohort study","volume":"75","author":"Su","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"2023121116132415500_bib10","article-title":"Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703","volume":"140","author":"Holtan","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023121116132415500_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137677","article-title":"Bridging the gap in access to transplant for underserved minority patients using mismatched unrelated donors and post-transplant cyclophosphamide: a National Marrow Donor Program\/be the Match (NMDP\/BTM) Initiative","volume":"136","author":"Shaw","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2023121116132415500_bib12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023121116132415500_bib13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/bbmt.2002.v8.pm11939602","article-title":"Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation","volume":"8","author":"Luznik","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2023121116132415500_bib14","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/JCM.03435-14","article-title":"Monitoring of cytomegalovirus viral loads by two molecular assays in whole-blood and plasma samples from hematopoietic stem cell transplant recipients","volume":"53","author":"Babady","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"issue":"1","key":"2023121116132415500_bib15","doi-asserted-by":"crossref","first-page":"85.e1","DOI":"10.1016\/j.bbmt.2020.10.009","article-title":"Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis","volume":"27","author":"Lin","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2023121116132415500_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/dof.2013.38.5.1946425","article-title":"Letermovir treatment of human cytomegalovirus infection antiinfective agent","volume":"38","author":"Verghese","year":"2013","journal-title":"Drugs Future"},{"issue":"1","key":"2023121116132415500_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2023121116132415500_bib18","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/s41590-022-01327-7","article-title":"Clonal expansion and epigenetic inheritance of long-lasting NK cell memory","volume":"23","author":"R\u00fcckert","year":"2022","journal-title":"Nat Immunol"},{"issue":"13","key":"2023121116132415500_bib19","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1084\/jem.20141172","article-title":"Cytomegalovirus generates long-lived antigen-specific NK cells with diminished bystander activation to heterologous infection","volume":"211","author":"Min-Oo","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"10","key":"2023121116132415500_bib20","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood-2011-04-347070","article-title":"NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions","volume":"118","author":"Foley","year":"2011","journal-title":"Blood"},{"issue":"23","key":"2023121116132415500_bib21","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023121116132415500_bib22","doi-asserted-by":"crossref","first-page":"510.e1","DOI":"10.1016\/j.jtct.2022.05.020","article-title":"Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"2023121116132415500_bib23","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.3390\/cancers13215572","article-title":"Letermovir prophylaxis and cytomegalovirus reactivation in adult hematopoietic cell transplant recipients with and without acute graft versus host disease","volume":"13","author":"Wolfe","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"2023121116132415500_bib24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s41669-021-00264-9","article-title":"Impact of letermovir use for cytomegalovirus prophylaxis on re-hospitalization following allogeneic hematopoietic stem cell transplantation: an analysis of a phase III randomized clinical trial","volume":"5","author":"Golan","year":"2021","journal-title":"Pharmacoecon Open"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2024014741","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7153\/2176253\/blooda_adv-2023-010966-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7153\/2176253\/blooda_adv-2023-010966-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T16:39:18Z","timestamp":1702312758000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/23\/7153\/498552\/Patterns-of-CMV-infection-after-letermovir"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":24,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010966","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2024014741","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]}}}